BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 86 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q1 2022. The put-call ratio across all filers is 15.47 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $199,235 | +4.1% | 69,420 | +83.2% | 0.00% | – |
| Q2 2023 | $191,350 | +166.5% | 37,891 | -0.2% | 0.00% | – |
| Q1 2023 | $71,788 | +5.0% | 37,983 | 0.0% | 0.00% | – |
| Q4 2022 | $68,369 | +6.8% | 37,983 | 0.0% | 0.00% | – |
| Q3 2022 | $64,000 | -31.2% | 37,983 | +0.4% | 0.00% | – |
| Q2 2022 | $93,000 | -82.4% | 37,838 | -80.1% | 0.00% | – |
| Q1 2022 | $527,000 | -50.9% | 189,946 | -5.7% | 0.00% | – |
| Q4 2021 | $1,074,000 | -37.6% | 201,455 | -1.0% | 0.00% | – |
| Q3 2021 | $1,722,000 | -32.8% | 203,454 | -3.2% | 0.00% | – |
| Q2 2021 | $2,563,000 | -45.5% | 210,287 | +8.5% | 0.00% | -100.0% |
| Q1 2021 | $4,700,000 | -28.1% | 193,744 | -5.0% | 0.00% | 0.0% |
| Q4 2020 | $6,539,000 | +5.1% | 204,020 | -0.8% | 0.00% | 0.0% |
| Q3 2020 | $6,220,000 | +12.3% | 205,743 | +56.6% | 0.00% | 0.0% |
| Q2 2020 | $5,538,000 | +81.2% | 131,345 | +7.2% | 0.00% | 0.0% |
| Q1 2020 | $3,057,000 | – | 122,506 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 2,014,858 | $17,046,000 | 0.60% |
| NEA Management Company, LLC | 3,449,845 | $29,186,000 | 0.35% |
| MPM BioImpact LLC | 248,506 | $2,102,000 | 0.33% |
| Artal Group S.A. | 1,646,517 | $13,930,000 | 0.31% |
| RA Capital Management | 2,589,904 | $21,911,000 | 0.30% |
| Bellevue Group AG | 3,463,000 | $29,297,000 | 0.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 760,128 | $6,431,000 | 0.13% |
| Ikarian Capital, LLC | 150,484 | $1,272,000 | 0.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 44,000 | $371,000 | 0.09% |
| Virtus ETF Advisers LLC | 16,600 | $140,000 | 0.06% |